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OBJECTIVE—In genome-wide association studies, performed mostly in nondiabetic individ-
uals, genetic variability of glucokinase regulatory protein (GCKR) affects type 2 diabetes-related
phenotypes, kidney function, and risk of chronic kidney disease (CKD). We tested whether
GCKR variability affects type 2 diabetes or kidney-related phenotypes in newly diagnosed type 2
diabetes.
RESEARCH DESIGN AND METHODS—In 509 GAD-negative patients with newly di-
agnosedtype2diabetes,we1)genotypedsixsinglenucleotidepolymorphismsinGCKRgenomic
region: rs6717980, rs1049817, rs6547626, rs780094, rs2384628, and rs8731; 2) assessed
clinical phenotypes, insulin sensitivity by the euglycemic insulin clamp, and b-cell function
by state-of-the-art modeling of glucose/C-peptide curves during an oral glucose tolerance test;
and 3) estimated glomerular ﬁltration rate (eGFR) by the Modiﬁcation of Diet in Renal Disease
formula.
RESULTS—The major alleles of rs6717980 and rs2384628 were associated with reduced
b-cell function (P , 0.05), with mutual additive effects of each variant (P , 0.01). The minor
alleles of rs1049817 and rs6547626 and the major allele of rs780094 were associated with
reduced eGFR according to a recessive model (P , 0.03), but with no mutual additive effects
of the variants. Additional associations were found between rs780094 and 2-h plasma glucose
(P , 0.05) and rs8731 and insulin sensitivity (P , 0.05) and triglycerides (P , 0.05).
CONCLUSIONS—Our ﬁndings are compatible with the idea that GCKR variability may
play a pathogenetic role in both type 2 diabetes and CKD. Genotyping GCKR in patients with
newly diagnosed type 2 diabetes might help in identifying patients at high risk for metabolic
derangements or CKD.
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G
lucokinase regulatory protein
(GCKR) is expressed in liver and,
to a lesser extent, in b-cells and ex-
erts an inhibitory effect on glucokinase
(GCK) by decreasing the afﬁnity of the
latter for glucose (1). Thus, it is in a key
position to regulate liver glucose balance
and, perhaps, glucose-stimulated insulin
secretion.
Allelic variability of two GCKR single
nucleotidepolymorphisms(SNPs),rs780094
and rs1260326, in strong linkage disequi-
librium(LD)witheachother,isassociated
with a number of human traits, including
serum triglyceride (2–5), fasting glucose
(2,5), C-reactive protein (6), coagulation
protein C (7), uric acid (8), insulin levels
(4), and susceptibility to type 2 diabetes
(2,4,5,9,10).Moreover,themissensevariant
P446 L of rs1260326 is associated with
reduced glomerular ﬁltration rate (esti-
mated glomerular ﬁltration rate [eGFR])
and increased risk of chronic kidney dis-
ease (CKD) (11). On the whole, the major
rs1260326 allele is associated with higher
fasting glucose and insulin, lower eGFR,
and increased CKD risk, but lower trigly-
cerides. Thus, this single allele seems to
be a multifaceted risk indicator of chronic
diseases.
Most studies reporting that GCKR
variation is associated with diabetes-
related intermediate phenotypes were per-
formed in nondiabetic individuals, and
surrogate markers, not state-of-art meth-
ods, were used to assess b-cell function or
insulin sensitivity (2,4,5,9,10). Because
both traits display a signiﬁcant spread in
patients with type 2 diabetes, the question
arises whether GCKR variants may affect
b-cell function in diabetic patients,
thereby potentially being a determinant
of type 2 diabetes heterogeneity, a marker
of the metabolic phenotype, or a tool to
select optimal therapy and to better de-
ﬁne prognosis. Moreover, because GCKR
is involved in the susceptibility to CKD,
it might help to select subgroups of pa-
tients with higher risk of renal complica-
tions.
We therefore undertook the present
investigation to test whether the genetic
variability of GCKR affects renal or b-cell
functioninpatientswithnewlydiagnosed
type 2 diabetes. We used the database of
the Verona Newly Diagnosed Type 2 Di-
abetes Study (VNDS), an ongoing inves-
tigation of patients with newly diagnosed
type 2 diabetes. This cohort was deemed
useful for our purposes because of the ab-
senceofthepotentiallyconfoundingeffects
of long-lasting antidiabetic treatments and
ofthelimitedimpactofdurationandsever-
ity of hyperglycemia per se on the meta-
bolic phenotypes.
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Pathophysiology/Complications
ORIGINAL ARTICLERESEARCH DESIGN AND
METHODS
VNDS
The VNDS is an ongoing study aiming at
building a biobank of patients with newly
diagnosed type 2 diabetes. A detailed
description of the study population and
experimental design is found in the
Supplementary Data. The current study
reports the data collected in 509 patients
whose characteristics are summarized in
Table 1.
Standard clinical parameters were
assessed in all patients. Metabolic tests
were carried out on two separate days in
random order. On one day, an oral glucose
tolerancetest(OGTT)(75g)wasperformed
to assess b-cell function, as previously de-
scribed (12). On a separate day, a euglyce-
mic insulin clamp was performed to assess
insulin sensitivity (13).
Analytic procedures
Plasma glucose concentration was mea-
sured in duplicate with a Beckman Glu-
cose Analyzer II (Beckman Instruments,
Fullerton,CA)atbedside.SerumC-peptide
and insulin concentrations were measured
by chemiluminescence as previously de-
scribed. Glycated hemoglobin and serum
lipids were measured by standard in-
house methods. GAD antibodies were
measuredbyimmunoradiometry(CentAK,
Medipan, Berlin-Dahlewitz, Germany), ac-
cording to the manufacturer’s instructions.
Serum creatinine was measured by Jaffe’s
reaction. Urinary albumin excretion was
measuredinanearlymorningurinesample
asthealbumin-to-creatinineratiobyanim-
munonephelometric method.
Calculations
eGFR was derived from serum creatinine
by the Modiﬁcation of Diet in Renal
Disease equation (14).
The amount of glucose metabolized
during the last 60 min of the clamp (M
value, reference insulin sensitivity) was
computed with standard formulae (13).
Thefollowingclassicindexesofb-cell
function were computed (15):
Insulinogenic index: (Insulin30’2 Insulin0’)/
(Glucose30’ 2Glucose0’), units: mU/mmol
CIR120’:Insulin120’/[Glucose120’*(Glucose 120’
2 3.89)], units: mU * L/mmol
2
in which CIR120’ is corrected insulin re-
sponse at 120’. Further insights in b-cell
function were sought by mathematic mod-
eling(seebelow and Supplementary Data).
Modeling of b-cell function
The analysis of the glucose and C-peptide
curves during the OGTTs of the VNDS
follows the general strategy described in
previous publications (12) and builds on
previous works from other laboratories
(16,17). Insulin secretion rate (ISR) is de-
scribed as the sum of two components,
one responding to the rate of increase of
glucose and one responding to the glucose
concentration itself. Modeling details are
found in Supplementary Tables 1 and 2.
There are two main physiologic out-
puts of the model:
1. derivative control [pmol z m
22 BSA] z
[mmol z L
21 z min
21]
21 of b-cell
function, which is presented as the
amountofinsulinsecretedinresponse
to a rate of glucose increase of 1 mmol/L
per minute that lasts for 1 min; and
2. proportional control of b-cell function,
which is presented as the stimulus-
response curve linking glucose con-
centration (x-axis) to ISR (pmol z
min
21 z m
22 BSA; y-axis) at the pre-
selected glucose concentrations of 5.5,
8.0, 11.0, 15.0, and 20.0 mmol/L.
Genotyping
A peripheral blood sample was collected
from each patient, and the DNA was ex-
tracted by standard salting-out method.
Six tag-SNPs (rs6717980, rs1049817,
rs6547626, rs780094, rs2384628, and
rs8731), which represent ;95% of the ge-
netic variability of this genomic region
(;610 kbp) (Supplementary Fig. 1), were
selected with the software GEVALT
(GEnotypeVisualization andALgorithmic
Tool) (18). The LD values in our popula-
tion, expressed as r
2, are consistent with
the values reported by HapMap and are
reported in Supplementary Fig. 1.
Genotypes were assessed by the high-
throughput genotyping Veracode tech-
nique (Illumina Inc., San Diego, CA),
applying the GoldenGate Genotyping As-
say according to the manufacturer’si n -
structions (19).
Statistical analysis
Data are presented as medians and inter-
quartile range, unless otherwise indi-
cated. Hardy-Weinberg equilibrium was
tested by x
2 test. Skewed variables were
log-transformed to improve the approxi-
mation to the Gaussian distribution. Sin-
gle variant association analyses were
carried out by generalized linear models
as implemented in SPSS (SPSS Inc.,
Chicago,IL).Whenstatisticallysigniﬁcant
differences were found in the propor-
tional control of b-cell function, the anal-
yses were repeated after adjusting for a
number of potential confounders, i.e.,
age, sex, BMI, and eGFR. Because the log-
arithmic transformation was insufﬁcient
to improve the distribution of the deriva-
tive control of b-cell function, the latter
Table 1—Clinical and metabolic features of the VNDS population
Variable Male Female All
n (M/F) 342 167 509
Age (years) 58 [51–65] 61 [55–66] 59 [52–65]
BMI (kg/m
2) 28.7 [26.2–32.4] 30.8 [27.4–34.5] 29.4 [26.5–33.2]
Waist (cm) 102 [94–112] 97 [91–104] 100 [93–108]
Fasting P-glucose (mmol/L) 7 [6.2–8.0] 7.3 [6.2–8.1] 7.1 [6.2–8.0]
2-h P-glucose (mmol/L) 13.7 [11.0–16.4] 13.3 [10.2–16.3] 13.5 [10.6–16.3]
HbA1c (%) 6.7 [6.1–7.6] 6.7 [6.2–7.4] 6.7 [6.2–7.5]
Triglycerides (mmol/L) 1.4 [1.0–2.1] 1.3 [1.0–2.0] 1.4 [1.0–2.0]
HDL cholesterol (mmol/L) 1.1 [1.0–1.3] 1.2 [1.0–1.4] 1.1 [1.0–1.4]
Cholesterol (mmol/L) 4.9 [4.2–5.5] 5.1 [4.5–5.8] 5.0 [4.3–5.6]
Systolic blood pressure (mmHg) 134 [120–150] 140 [130–150] 138 [124–150]
Diastolic blood pressure (mmHg) 82 [80–90] 85 [80–90] 84 [80–90]
Insulin sensitivity (mmol/min/m
2 BSA) 565 [314–834] 546 [394–755] 559 [351–800]
Insulinogenic index (mU/mmol) 3.5 [2.0–5.8] 4.6 [2.3–8.1] 3.8 [2.0–6.7]
CIR120’ (mU 3 L/mmol
2) 0.4 [0.2–1.1] 0.6 [0.2–1.4] 0.5 [0.2–1.2]
eGFR (mL/min/1.73 m
2) 84.4 [74.7–96.3] 74.9 [62.5–86.1] 80.0 [70.3–93.4]
Urinary albumin/creatinine
(mg/mmol) 0.8 [0.4–3.1] 0.6 [0.3–1.5] 0.8 [0.4–2.5]
Serum creatinine (mmol/L) 82 [74–90] 69 [62–80] 79 [68–88]
Data are presented as median [interquartile range].
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GCKR and renal, b-cell function in diabeteswas ﬁrst analyzed by Kruskal-Wallis test,
and if statistically signiﬁcant differences
were found, a multivariate analysis of the
log-transformed value was performed, ad-
justing for age, sex, BMI, and eGFR. All
statistical analyses were carried out with
the SPSS 12.0 software. Statistical signiﬁ-
cance was declared at P , 0.05.
RESULTS
Clinical features of the study
population
Anthropometric, clinical, and metabolic
featuresofthestudysubjectsareshownin
Table1.Mostpatientswereoverweightor
obese, but less than 50% were obese.
However, abdominal obesity was present
in;50%ofmalepatientsandin.75%of
female patients. Glucose control, as mea-
suredbyHbA1c,wasfairlygoodwith25%
patients having HbA1c .7.4%. High tri-
glyceride and low HDL-cholesterol levels
were common, especially the latter in the
female patients. Systolic and diastolic hy-
pertensive values were detected in 50 and
25% of the patients, respectively.
Effects of GCKR variants on b-cell
and kidney functions
Allele distribution was compatible with
the Hardy-Weinberg equilibrium in all
six SNPs (P $ 0.19).
Anthropometric, clinical, and meta-
bolic features of the study subjects, lay-
eredaccordingtors6717980,rs1049817,
rs6547626, rs780094, rs2384628, and
rs8731 alleles, are shown in Supplementary
Tables 3–8.
Both rs6717980 and rs2384628 were
signiﬁcantly related to b-cell function.
Carriers ofthe major(A) rs6717980allele
displayed a signiﬁcant reduction in the
proportional control of b-cell function,
i.e., the curve relating glucose (stimulus)
to ISR (response), according to a domi-
nant model (P , 0.02, Supplementary
Fig. 2). Carriers of the major (C)
rs2384628 allele showed a signiﬁcant
impairmentinboththederivativecontrol,
i.e., the response of b-cell to the rate of glu-
cose increase (2108 6 47.7 [pmol z
m
22 BSA] z [mmol z L
21 z min
21]
–1 [P ,
0.03], according to an additive model
[Table 2]), and the proportional control
of b-cell function (P , 0.04 with a domi-
nant model, Supplementary Fig. 2).
The effects of rs6717980 and
rs2384628genotypesontheproportional
control of b-cell function, i.e., the curve
relating glucose to ISR, were statistically
independentofeachother(P,0.005and
P , 0.04, respectively, in a multivariate
model including both SNPs), consistent
with their low degree of LD. Therefore,
we computed a GCKR score by counting
one each rs6717980 A allele or each
rs2384628 C allele carried by each sub-
ject. The GCKR score could range from a
minimum of 0 (a genotype with neither
rs6717980 A nor rs2384628 C alleles)
to a maximum of 4 (a rs6717980 AA/
rs2384628 CC genotype) (Supplementary
Table 9). The higher the GCKR score, the
lower the ISR in response to glucose (i.e.,
theproportionalcontrolofb-cellfunction)
(Fig. 1, Supplementary Table 10) (unad-
justed P = 0.005). The P value of the
GCKR score stayed statistically signiﬁcant
(P=0.006)afterincludinginamultivariate
model rs7901695 or rs7903146, the two
TCF7L2 variants related to b-cell function
in the VNDS (13).
Three GCKR variants were found to
be related to kidney function. The minor
alleles of both rs1049817 and rs6547626
(rs1049817: 23.35 6 1.3 mL/min/
1.73 m
2 BSA per G allele, P = 0.01;
rs6547626: 23.24 6 1.3 mL/min/
1.73 m
2 BSA per A allele, P = 0.013) and
the diabetes risk G allele of rs780094
(22.56 6 1.2 mL/min/1.73 m
2 BSA per
G allele, P = 0.038) were associated with
reduced eGFR. Consistent with their
high LD (Supplementary Fig. 1), in
multivariate analysis, these three variants
were not signiﬁcantly associated with
eGFR independently of each other (data
not shown), suggesting that they may be
indicators of the same genetic source of
eGFR variation.
Other associations of GCKR
variants to metabolic phenotypes
Carriers of the diabetes risk G allele of
rs780094 had somewhat lower OGTT
2-h glucose (20.55 6 0.27 mmol/L,
P , 0.05) (Supplementary Table 6). The
major (G) allele of rs8731 was associated
with increased triglycerides (+0.09 6
0.04 log units; P , 0.04), higher systolic
blood pressure (+2.66 6 1.38 mmHg;
P = 0.05), and lower insulin sensitivity
(20.1 6 0.04 log units according to a re-
cessive model, P , 0.04) (Supplementary
Table 8). These associations stayed statis-
tically signiﬁcant after adjusting for age,
sex, BMI, and eGFR.
CONCLUSIONS—The current study
tested the potential role(s), if any, of six
GCKR variants (Supplementary Fig. 1),
purposely selected to capture ;95% of
common GCKR variability, in determin-
ing b-cell and kidney functions in pa-
tients with newly diagnosed type 2
diabetes in the VNDS. We also genotyped
rs780094 because of its reported role in
glucose regulation and type 2 diabetes
risk (2,4,5,9,10). Novelties of our study
include: 1) the use of state-of-art methods
(16,17,20,21) to assess b-cell function
and insulin sensitivity; and 2)t h es e l e c -
tion of the study sample, composed of
patients with newly diagnosed type 2 di-
abetes, thereby presumably devoid of the
phenotype-modifying effects of long-
standing hyperglycemia or pharmaco-
logic antidiabetic treatment.
Our data show that two (rs6717980
and rs2384628) of six GCKR SNPs
exerted a strong, independent inﬂuence
on b-cell function (Table 2, Supplementary
Fig. 2). Indeed, homozygous carriers of
“poor” b-cell function alleles at both
SNPs had an ;60% reduction in the in-
sulin secretory response to glucose, when
compared with homozygous carriers of
“good” b-cell function alleles at both
SNPs (Fig. 1).
This ﬁnding has three implications.
First, as already shown by us for TCF7L2
(13),aroleofGCKRindeterminingb-cell
Table 2—Derivative control of b-cell function in patients of the VNDS according to
genotype of GCKR variants
GCKR SNP n MAF AA AB BB b SE P value
rs6717980 487 0.32 657.6 6 52.2 639.4 6 47.0 643.4 6 102.9 0.14 0.21 0.52
rs1049817 486 0.35 649.6 6 52.3 612 6 48.5 736.5 6 91.6 0.16 0.21 0.45
rs6547626 492 0.34 645.4 6 50.3 609.1 6 49.3 744.2 6 619.8 0.16 0.20 0.42
rs780094 492 0.47 620.8 6 66.3 634.8 6 49.6 676.2 6 57.5 0.19 0.19 0.33
rs2384628 493 0.46 558.1 6 54.3 651.8 6 45.8 760.6 6 88.7 0.43 0.20 0.03
rs8731 483 0.21 652.9 6 42.8 635.6 6 58.8 716.1 6 160.8 20.02 0.24 0.95
Data are presented as mean 6 SE. Variables were log-transformed before statistical analysis to approximate
a Gaussian distribution; the coefﬁcient b and its SE refer to log-transformed values. The analysis was per-
formed adjusting for age, sex, and BMI. A, major allele; B, minor allele; MAF, minor allele frequency.
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Bonetti and Associatesfunctioncanbedetectedinovertdiabetes.
Thus, recognizing and assessing genetic
heterogeneity in patients with type 2 di-
abetes might turn out to be valuable in
planning personalized therapies and
outlining a “metabolic” prognosis. Sec-
ond, despite its reported low expression
in human b-cells (1), GCKR,o rg e n o m i c
areas closely related to it, may play a rel-
evant role in regulating the insulin secre-
tory response to glucose in humans (Fig.
1). Further studies will be needed to elu-
cidate the role, if any, played by GCKR in
human b-cell function at the molecular
level. Third, the two SNPs associated
with b-cell function in our study are in
low LD with each other (Supplementary
Fig. 1) and play an additive role in regu-
lating glucose-stimulated insulin secre-
tion (Fig. 1). Thus, multiple regions of
GCKR are likely to be relevant for b-cell
function in humans. Detailed genetic
studiesmaybeneededtoclarifythisissue.
In agreement with a recently pub-
lished genome-wide association study
(11),threeofsixGCKRSNPs,inrelatively
high LD with each other (Supplementary
Fig. 1), were signiﬁcantly associated with
eGFR (Fig. 2) but not to microalbuminu-
ria (Supplementary Tables 3–8), accord-
ing to an apparently recessive model.
B e c a u s en o n eo ft h e s et h r e eS N P s
maintained a statistically signiﬁcant asso-
ciation with eGFR in multivariate models
with simultaneous adjustment for the
other two variants, we argue that these
variants may reﬂect the presence of one
common genetic source of phenotypic
variation (Fig. 2).
A substantial fraction of patients with
type 2 diabetes have a reduction in GFR
without microalbuminuria, and, vice
versa, a substantial fraction of micro-
albuminuric patients have normal GFR
(22,23). A mild-to-moderate reduction of
eGFR predicts cardiovascular disease in
patients with type 2 diabetes, also inde-
pendently of classic risk factors (24). Our
ﬁnding that GCKR variation inﬂuences
eGFR in patients with newly diagnosed
type 2 diabetes supports the hypothesis
of a genetic basis for nonalbuminuric
C K Di nt h i sd i s e a s ea n d ,p o s s i b l y ,f o r
the incremental cardiovascular risk re-
lated to this trait. Furthermore, the G
allele of rs780094 is both a risk allele for
type 2 diabetes (4,5,9,10) and, in this
study, a marker of reduced eGFR (Fig.
2). This suggests that a genetic common-
ality between type 2 diabetes and nonal-
buminuric CKD may exist and that the
clock for CKD in these patients may start
t i c k i n gl o n gb e f o r et h eo n s e to ft y p e2
diabetes. Although GCKR can be consid-
ered a candidate gene for glucose- and tri-
glyceride-related (see below) phenotypes,
the molecular mechanisms, if any, linking
GCKR to eGFR and CKD are currently
unknown.
The G allele of rs8731 was associated
with increased triglycerides, increased
systolic blood pressure, and reduced in-
sulinsensitivity(SupplementaryTable8).
The effect was quantitatively small and
not replicated in the immediately preced-
ing SNP; this, therefore, may be a chance
ﬁnding. On the other hand, this cluster of
variables belongs to the metabolic syn-
drome, and the quantitative magnitude
(;60 mmol/min/m
2 BSA) of this putative
effect of GCKR v a r i a t i o no nw h o l e - b o d y
insulin sensitivity is consistent with the
Figure 1—Effects of GCKR score on the curve relating ISR (y-axis) to glucose concentration
(x-axis), i.e., the proportional control of b-cell function, in patients with newly diagnosed type 2
diabetes in the VNDS. The GCKR score was computed by counting one per each rs6717980 A
allele and one per each rs2384628 C allele carried by each subject. The GCKR score could range
from a minimum of 0 (a carrier of neither rs6717980 A alleles nor rs2384628 C alleles) to
a maximum of 4 (a carrier of both AA in rs6717980 and CC in rs2384628). The higher the total
score, the lower the b-cell insulin secretory response to glucose (unadjusted values were used for
thegraph; unadjustedP=0.005;P=0.012afteradjustingforage, sex,BMI,and eGFR).Data are
presented as mean 6 SEM.
Figure 2—Relationships between rs1049817, rs6547626, and rs780094 genetic variability and
eGFR in patients with newly diagnosed type 2 diabetes in the VNDS. The G allele of rs1049817,
the A allele of rs6547626, and the type 2 diabetes risk G allele of rs780094 were associated with
reduced renalfunction(P#0.01),according to arecessive model.Data arepresentedasmean6
SEM. GFR, glomerular ﬁltration rate; MDRD, Modiﬁcation of Diet in Renal Disease.
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GCKR and renal, b-cell function in diabetesrole played by GCK, the protein regu-
lated by GCKR, in determining insulin-
mediated glucose trafﬁci nl i v e r .O u r
ﬁndings suggest a potential genetic basis
for the clustering of these three traits (pos-
sibly including the cardiovascular risk they
convey) in the same diabetic patient. Rep-
lication of this result in an independent
cohort is needed.
Our study has a number of limita-
tions.First,patientsoftheVNDSarenota
population-based sample, although com-
parison of their features with previously
published studies suggests that they are
fairly representative of Italian patients
with type 2 diabetes (25). However, the
VNDScohorthasasomewhathigherthan
expected prevalence of the male sex, pos-
sibly reﬂecting a sex-related referral bias.
Second, although we used state-of-art
methods to assess b-cell function and in-
sulin sensitivity (16,17,20,21), many rel-
evant pathophysiologic facets were
unexplored, e.g., incretin role and liver
versus peripheral insulin resistance.
Third, as in all association studies, our
ﬁndings need to be replicated in an inde-
pendent sample of patients. Fourth, our
study was performed in Italian patients;
extrapolations to other ethnic groups
should be made with caution. Fifth, the
P values we report were not adjusted for
multiplecomparisons,andthismayresult
in statistical type I errors, although, in the
case of GCKR, a gene well known to be
implicated in the regulation of diabetes
andCKD-relatedphenotypes,corrections
for multiple comparisons might result in
statistical type II errors.
In summary, we have reported that
GCKR variation is signiﬁcantly related in
multiple ways to b-cell function and kid-
ney function in patients with newly diag-
nosed type 2 diabetes. Thus, GCKR may
play a polyvalent role in human disease,
and assessing its variation might prove to
be a useful tool to personalize the treat-
ment and to reﬁne the prognosis of pa-
tients with type 2 diabetes.
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